The Food and Drug Administration has decided to delay its approval for new diabetes drug, dapagliflozin, created jointly by AstraZeneca and Bristol-Myers Squibb.  Regulators in the U.S. said that they cannot approve the experimental drug without more data. AstraZeneca and Bristol-Myers Squibb have announced that they are working with the FDA to determine their next steps and are in ongoing discussions... 

AstraZeneca has announced that the company will be trimming its US sales force by nearly one-fourth as it seeks to reduce costs.  The company expects to cut around 1,150 sales representative and management jobs, charging between $50 million and $100 million in costs in the fourth quarter.  The cost of the cuts will not have any impact on the company’s guidance for core earnings per share for 2011...